Brief: Cognition Therapeutics And The Alzheimer's Clinical Trials Consortium Initiate First Clinical Site In The Phase 2 Start Study In Early Alzheimer’s Disease
05/07/2023 12:30
July 5 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS AND THE ALZHEIMER'S CLINICAL TRIALS
CONSORTIUM INITIATE FIRST CLINICAL SITE IN THE PHASE 2 START
STUDY IN EARLY ALZHEIMER’S DISEASE
Source text for Eikon: ID:nGNX3Rb96n
Further company coverage: CGTX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB